Ian Rees, Director and Head of Personal Injury at JCP Solicitors, which has an office in Caerphilly, shares some positive news for mesothelioma patients in Wales.
Our Asbestos Team is delighted to learn that the first immunotherapy treatment for 14 years is to be made available by the NHS for mesothelioma patients in England and Wales.
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of nivolumab and ipilimumab for first-line treatment of adults with nresectable malignant pleural mesothelioma (MPM) in England and Wales.
The NICE committee also recommended extending the guidance of nivolumab plus ipilimumab to treat rarer forms of mesothelioma in the lining of the heart and abdomen.
Mesothelioma is a cancer related to exposure to asbestos, and it is often diagnosed late, giving patients an average of less than a year’s survival without treatment. Exposure to asbestos in the workplace is responsible for more than 80 percent of cases. We act for a number of sufferers and their families, working hard to secure them the financial support they need to access specialist care.
To get tailored advice from our team about a possible asbestos claim or other accident or injury you have incurred due to no fault of your own, please get in touch on: 02920 860628 or: ian.rees@jcpsolicitors.co.uk.
